What is the optimal dose of botulinum toxin A in the treatment of cervical dystonia? Results of a double blind, placebo controlled, dose ranging study using Dysport
Werner Poewe(Innsbruck Medical University), G. Künig, R. Benecke(Children's Hospital of Philadelphia), Günther Deuschl(Christian-Albrechts-Universität zu Kiel), WH Oertel(National Institute of Mental Health), E. Feifel, A Nebe, Andrés Ceballos-Baumann(Schön Klinik München Schwabing), Jörg Wissel(University of Potsdam), Kirn R. Kessler(Heinrich Heine University Düsseldorf), A Ohly
Cited by 219
Related Papers
MDS clinical diagnostic criteria for Parkinson's disease
|Movement Disorders|2015|7.4k
Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria
|Movement Disorders|2017|2.3k
Genome-wide association study reveals genetic risk underlying Parkinson's disease
|Nature Genetics|2009|2k
The Parkinson Progression Marker Initiative (PPMI)
|Progress in Neurobiology|2011|1.9k
Neurostimulation for Parkinson's Disease with Early Motor Complications
|New England Journal of Medicine|2013|1.4k